Merocarb

Meropenem, the active ingredient in Merocarb, is a carbapenem antibiotic presented as an intravenous formulation for hospital use. It is employed to treat severe bacterial infections, including intra‑abdominal infections, pneumonia, meningitis, urinary tract infections, sepsis, and skin‑soft‑tissue infections in adult patients. These infections are typically acquired in healthcare settings and may involve multidrug‑resistant organisms.

GNH USA supplies Merocarb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets.

Merocarb (meropenem) is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections in hospitalized patients.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with perforated or postoperative abdominal infections. - Nosocomial pneumonia: provides effective coverage against Gram‑negative and Gram‑positive pathogens causing hospital‑acquired lung infection. - Meningitis: penetrates the cerebrospinal fluid to eradicate causative organisms in bacterial meningitis. - Severe urinary tract infections: resolves infection caused by resistant uropathogens in complicated UTIs. - Sepsis: rapidly reduces bacterial load in systemic bloodstream infections. - Skin and soft tissue infections: treats deep or necrotizing infections caused by susceptible bacteria.

Adverse reactions to Merocarb may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Diarrhea: loose stools that may be watery. - Rash: skin erythema or pruritus.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction with respiratory and circulatory compromise. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea.

When using Merocarb, clinicians should consider several safety measures.

- Renal function: assess and adjust dose in patients with impaired kidney function. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams. - Seizure risk: monitor closely in patients with a history of epilepsy or CNS disorders. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Concomitant nephrotoxic drugs: evaluate renal safety when combined with other kidney‑affecting agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Merocarb may interact with several medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Valproic acid: co‑administration can lower valproate levels and precipitate seizures. - CNS stimulants (e.g., tramadol): increase risk of seizure activity. - High‑dose aminoglycosides: additive nephrotoxicity may occur. - Loop diuretics: may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Probenecid: can raise meropenem plasma concentrations. - Warfarin: monitor INR as antibiotic may alter anticoagulant effect. - Oral contraceptives: possible reduction in efficacy; advise additional contraceptive measures.